William G. Wierda, MD, PhD, professor in the department of leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses data surrounding the use of ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) as a treatment option for both patients with newly diagnosed chronic lymphocytic leukemia (CLL) as well as relapsed CLL.
At the 2018 ASH Annual Meeting, several trials reported on this combination in CLL. MD Anderson has a clinical trial including 2 cohorts of patients: a relapsed cohort and a frontline cohort. Wierda also says the CLARITY trial, reported by the UK Group, looked at this combination in relapsed patients, while the Ohio State Comprehensive Cancer Center has a trial investigating this combination plus a CD20 antibody.
Across all these studies, Wierda says there have been very high complete remission rates in both the frontline and relapsed setting. There was a very high proportion of minimal residual disease (MRD)-negative disease. Also, there were no new toxicities or safety concerns above what is expected of these agents as monotherapy.
For more resources and information regarding anticancer targeted therapies in CLL: [ Ссылка ]
